Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
br Experimental procedures br Results br Discussion
2023-07-28
Experimental procedures Results Discussion Although previous studies have indicated that astrocyte aromatase plays a role in nociceptive processes (O'Brien et al., 2015, Smeester et al., 2016), the mechanisms responsible for the regulation of aromatase and its involvement in nociception rem
-
The presence of crown like structures and inflammatory facto
2023-07-28
The presence of crown-like structures and inflammatory factors in the breast of obese patients is associated with considerable changes in intracellular signaling and a profound cellular dysfunction. Secreted pro-inflammatory factors can directly promote breast carcinogenesis as they have been repor
-
Non steroidal anti inflammatory drugs which include
2023-07-28
Non-steroidal anti-inflammatory drugs, which include aspirin and ibuprofen, target COX-2 activity to inhibit inflammation. It has been shown that daily use of a nonsteroidal anti-inflammatory drugs is associated with reduced ER-positive breast cancer recurrence in obese and overweight women. More p
-
Regarding progression free survival analyzing clinical trial
2023-07-28
Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, pSU6656 of improvement of PFS only is that after antiangiogenic therapy glioblastomas appear
-
Another hypothesis is angiogenesis inhibition Angiogenesis
2023-07-28
Another hypothesis is angiogenesis inhibition. Angiogenesis is a process that involves the growth, migration and differentiation of endothelial plx4032 to form new blood vessels. Angiogenesis favorably influences tumor growth and also influences tumor invasion of vessels, resulting in tumor metastas
-
During the course of angiogenesis the overactivated
2023-07-28
During the course of angiogenesis, the overactivated angiogenic stimulators are responsible for carrying out abnormal proliferation in the retinal microvasculature, resulting in the formation of various immature blood vessels. These newly formed blood vessels become the prime spots for leakage of th
-
br Summary and future br Introduction Androgen activity is c
2023-07-28
Summary and future Introduction Androgen activity is critical for a wide range of developmental and physiological responses and is especially important in male sexual differentiation and maturation. The biological activity of androgens occurs through binding to the androgen receptor (AR) and t
-
This development notwithstanding the chemotherapeutic treatm
2023-07-28
This development notwithstanding, the chemotherapeutic treatment for leukemia has stagnated over the last 40 years [35]. Main treatment options necessitate aggressive chemotherapy to target leukemic cells [36], [37], [38], [39]. Several limitations of current treatment options include the use of ant
-
Since all the above vascular and glomerular effects contribu
2023-07-28
Since all the above vascular and glomerular effects contribute to blood pressure regulation, it is expected for 12/15-LOX pathway to play a role in pathogenesis of hypertension (Fig. 6). Indeed, there is evidence for alterations of the 12- and 15LOX enzymes and metabolites both in humans with essent
-
Several ceritinib resistant mutations following the second l
2023-07-28
Several ceritinib-resistant mutations following the second-line treatment of ALK+-NSCLC have been discovered [64]. These mutations include C1156Y, F1174L, and L1152R, which were first observed in crizotinib-resistant tumor samples. The G1202R ceritinib-resistant mutation occurs within the hinge and
-
br Discussion The patient presented initially
2023-07-28
Discussion The patient presented initially only with parietal symptoms in the form of acalculia, visuo-spatial deficits, and visuo-perceptual deficits and dressing apraxia. He also had simultognosia as early symptoms. Later when the disease progressed he had recent memory deficits and language in
-
Lorlatinib is an orally active brain penetrant cyclic aminop
2023-07-28
Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
L-α-Aminoadipic Acid br Disclosure br Acknowledgments br Int
2023-07-28
Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small L-α-Aminoadipic Acid that target genetic mutations known to play critical roles in the progression to metastatic disease. Mutations in
-
The direction of glutamate transport
2023-07-28
The direction of glutamate transport by the cell membrane transporter is reversible. As mentioned above, glutamate transport is an electrogenic process associated with a transmembrane ion gradient established by the Na+-K+ pump through hydrolysis of adenosine triphosphate. Under conditions of energy
-
br Conclusions Triptans are HT B D F
2023-07-28
Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan
16071 records 279/1072 page Previous Next First page 上5页 276277278279280 下5页 Last page